Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;102(6):e229-e232.
doi: 10.3324/haematol.2016.157768. Epub 2017 Mar 9.

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century

Janick Weberpals  1 , Dianne Pulte  2 , Lina Jansen  1 , Sabine Luttmann  3 , Bernd Holleczek  4 , Alice Nennecke  5 , Meike Ressing  6   7 , Alexander Katalinic  8 , Maximilian Merz  9 , Hermann Brenner  1   10   11 ; GEKID Cancer Survival Working Group
Affiliations

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century

Janick Weberpals et al. Haematologica. 2017 Jun.
No abstract available

PubMed Disclaimer

References

    1. Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98(2):222–229. - PMC - PubMed
    1. Pulte D, Jansen L, Castro FA, Brenner H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031–2040. - PubMed
    1. Sant M, Minicozzi P, Mounier M, et al. Surival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. - PubMed
    1. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(2):2133–2142. - PubMed
    1. Palumbo A, Bringhen S, Larocca A, et al. Brotezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634–640 - PubMed

Publication types

LinkOut - more resources